SMAD3 and ovarian cancer: Recent investigations indicated that elevated expression of miR-489 blocked cell growth, invasion and EMT by targeting Shp2 in hypopharyngeal carcinoma [145], SMAD3 in breast cancer [146], AKT3 in ovarian cancer [147], and Dek in ovarian cancer, as well as muscle stem cells [147,148].